The real-world data collection focuses on Ruxolitinib cream, a groundbreaking topical medication2 that is first in the world to be indicated for the treatment of nonsegmental vitiligo3
• No new treatment for vitiligo in the last decade; current topical medications have limited success in stopping the spread of vitiligo and encouraging repigmentation4
• Ruxolitinib cream, the first medication indicated for the treatment of nonsegmental vitiligo, is pending regulatory approvals in Singapore and in South-East Asia end 2025/early 2026
• Until then, NSC, a specialist dermatological centre of NHG Health, is excited to be the first healthcare institution in Singapore to provide vitiligo patients an innovative treatment on a large-scale through a special access route under the Health Sciences Authority
Singapore, 25 August 2025 – The National Skin Centre (NSC), a specialist dermatological centre of NHG Health – a leading public healthcare group in Singapore – is pushing the boundaries of science for vitiligo patients by embarking on the largest real-world data collection on vitiligo in South-East Asia. This real-world data collection will help address critical knowledge gaps on vitiligo in our region.
“Current studies on the effectiveness of Ruxolitinib are conducted mainly on Western populations, hence experience on the effectiveness of the treatment for Asian population is lacking. This real-world experience data collection will fill the knowledge gap,” said Prof Steven Thng Tien Guan, Deputy Director of NSC, NHG Health, and Consultant in-Charge of its Pigment Clinic.
